Xilio Therapeutics Reports Q2 Results, Cash Runway Into Q1 2028, NSCLC Data in H2 2027
XLO sits 42% above its 52-week low of $6.465 on light trading volume (0.1× avg).
Summary
Xilio Therapeutics reported Q2 2026 financial results, with no specific numbers disclosed. The company expects its cash runway to extend into Q1 2028, a slight refinement from the prior 'early 2028' guidance provided in the Q1 10-Q. Initial Phase 1 data in metastatic non-small cell lung cancer (NSCLC) is now expected in H2 2027, a new timeline disclosure. The update follows the May 2026 S-3/A shelf amendment and the June 2026 shareholder approval of an expanded stock incentive plan. The cash runway extension and pipeline timeline provide incremental clarity for a small-cap biotech with a market cap around $60 million.
At the time of this announcement, XLO was trading at $9.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $60.4M. The 52-week trading range was $6.47 to $12.74. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.